沙库巴曲缬沙坦钠联合达格列净对射血分数降低心力衰竭的治疗效果评价  

Evaluation of the therapeutic effect of entresto combined with dapagliflozin on heart failure with reduced ejection fraction

作　　者：张世琳 余占彪 ZHANG Shiling;YU Zhanbiao(Department of Cardiology,Qingyang People’s Hospital,Qingyang,Gansu 745000,China)

机构地区：[1]庆阳市人民医院心血管内科,甘肃庆阳745000

出　　处：《现代医药卫生》2025年第2期390-393,共4页Journal of Modern Medicine & Health

摘　　要：目的分析射血分数降低心力衰竭临床治疗中采取沙库巴曲缬沙坦钠与达格列净联用方案的临床效果。方法收集2023年2月至2024年2月该院收治并提供诊疗的76例射血分数降低心力衰竭患者,参考电脑随机数表法将患者分作对照组和试验组,各38例。对照组给予沙库巴曲缬沙坦钠治疗,试验组予以沙库巴曲缬沙坦钠与达格列净联用方案治疗,对比分析2组临床疗效、心功能、心肌受损状况及预后情况。结果治疗后,试验组患者总有效率为94.74%(36/38),比对照组的76.32%(29/38)更高,差异有统计学意义(P<0.05)。同时,试验组的左室舒张末期内径(LVEDD)值与左室收缩末期内径(LVESD)值均短于对照组,而左室射血分数(LVEF)高于对照组,氨基末端脑钠肽前体(NT-proBNP)、心肌钙蛋白I(cTnI)及肌酸激酶同工酶(CK-MB)水平均低于对照组,且心血管不良事件的发生率也低于对照组,差异均有统计学意义(P<0.05)。结论射血分数降低心力衰竭临床治疗中采取沙库巴曲缬沙坦钠与达格列净联用方案不仅能提高患者临床疗效,改善心功能,还能降低心肌受损程度,促进预后水平改善。Objective To analyze the clinical effect of the combination of entresto and dapagliflozin in the clinical treatment of heart failure with reduced ejection fraction.Methods A total of 76 patients with heart failure with reduced ejection fraction admitted to the hospital and provided for diagnosis and treatment were collected from February 2023 to February 2024.The patients were divided into control group and experimental group according to the computer random number table method,38 cases in each group.The control group was treated with entresto,and the experimental group was treated with entresto combined with dapagliflozin.The clinical efficacy,cardiac function,myocardial damage and prognosis of the two groups were compared and analyzed.Results After treatment,the total effective rate of the experimental group was 94.74%(36/38),which was higher than 76.32%(29/38)of the control group,and the difference was statistically significant(P<0.05).At the same time,the left ventricular end-diastolic diameter(LVEDD)value and left ventricular end-systolic diameter(LVESD)value of the experimental group were shorter than those of the control group,while the left ventricular ejection fraction(LVEF)was higher than that of the control group.The levels of N-terminal pro-brain natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI)and creatine kinase isoenzyme(CK-MB)were lower than those of the control group,and the incidence of cardiovascular adverse events was also lower than that of the control group,the differences were statistically significant(P<0.05).Conclusion The combination of entresto and dapagliflozin in the clinical treatment of heart failure with reduced ejection fraction can achieve significant results.It can not only improve the clinical efficacy of patients,improve cardiac function,but also reduce the degree of myocardial damage and promote the improvement of prognosis.

关 键 词：射血分数降低心力衰竭 沙库巴曲缬沙坦钠 达格列净 临床效果 心功能 心肌受损 

分 类 号：R541.61[医药卫生—心血管疾病]